BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37762046)

  • 1. Enhancement of Radiation Therapy through Blockade of the Immune Checkpoint, V-domain Ig Suppressor of T Cell Activation (VISTA), in Melanoma and Adenocarcinoma Murine Models.
    Duval KEA; Tavakkoli AD; Kheirollah A; Soderholm HE; Demidenko E; Lines JL; Croteau W; Zhang SC; Wagner RJ; Aulwes E; Noelle RJ; Hoopes PJ
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors.
    Iadonato S; Ovechkina Y; Lustig K; Cross J; Eyde N; Frazier E; Kabi N; Katz C; Lance R; Peckham D; Sridhar S; Talbaux C; Tihista I; Xu M; Guillaudeux T
    Front Immunol; 2023; 14():1311658. PubMed ID: 38152397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner.
    Thakkar D; Paliwal S; Dharmadhikari B; Guan S; Liu L; Kar S; Tulsian NK; Gruber JJ; DiMascio L; Paszkiewicz KH; Ingram PJ; D Boyd-Kirkup J
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
    Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer.
    Fujiwara K; Saung MT; Jing H; Herbst B; Zarecki M; Muth S; Wu A; Bigelow E; Chen L; Li K; Jurcak N; Blair AB; Ding D; Wichroski M; Blum J; Cheadle N; Koenitzer J; Zheng L
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32675194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.
    Liu J; Yuan Y; Chen W; Putra J; Suriawinata AA; Schenk AD; Miller HE; Guleria I; Barth RJ; Huang YH; Wang L
    Proc Natl Acad Sci U S A; 2015 May; 112(21):6682-7. PubMed ID: 25964334
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Baniel CC; Heinze CM; Hoefges A; Sumiec EG; Hank JA; Carlson PM; Jin WJ; Patel RB; Sriramaneni RN; Gillies SD; Erbe AK; Schwarz CN; Pieper AA; Rakhmilevich AL; Sondel PM; Morris ZS
    Front Immunol; 2020; 11():1610. PubMed ID: 32849544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-Affinity Anti-VISTA Antibody Protects against Sepsis by Inhibition of T Lymphocyte Apoptosis and Suppression of the Inflammatory Response.
    Tao T; Bo L; Li T; Shi L; Zhang H; Ye B; Xu Y; Ma Q; Deng X; Zhang G
    Mediators Inflamm; 2021; 2021():6650329. PubMed ID: 34366711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXD3 Regulates VISTA Expression in Melanoma.
    Rosenbaum SR; Knecht M; Mollaee M; Zhong Z; Erkes DA; McCue PA; Chervoneva I; Berger AC; Lo JA; Fisher DE; Gershenwald JE; Davies MA; Purwin TJ; Aplin AE
    Cell Rep; 2020 Jan; 30(2):510-524.e6. PubMed ID: 31940493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
    Han MG; Jang BS; Kang MH; Na D; Kim IA
    Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma Cell Intrinsic GABA
    Pomeranz Krummel DA; Nasti TH; Kaluzova M; Kallay L; Bhattacharya D; Melms JC; Izar B; Xu M; Burnham A; Ahmed T; Li G; Lawson D; Kowalski J; Cao Y; Switchenko JM; Ionascu D; Cook JM; Medvedovic M; Jenkins A; Khan MK; Sengupta S
    Int J Radiat Oncol Biol Phys; 2021 Mar; 109(4):1040-1053. PubMed ID: 33289666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
    Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
    Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin attenuates V-domain Ig suppressor of T-cell activation through the aryl hydrocarbon receptor pathway in Melanoma: In Vivo and In Vitro Studies.
    Alanazi FE; As Sobeai HM; Alhazzani K; Al-Dhfyan A; Alshammari MA; Alotaibi M; Al-Hosaini K; Korashy HM; Alhoshani A
    Saudi Pharm J; 2022 Feb; 30(2):138-149. PubMed ID: 35528855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of PD-1 Checkpoint Blockade and Botulinum Toxin Type A1 Improves Antitumor Responses in Mouse Tumor Models of Melanoma and Colon Carcinoma.
    Kwak S; Lee JY; Kim MJ; Lee HJ; Lee DK; Kang J; Kang WH; Son WC; Cruz DJM
    Immunol Invest; 2023 Nov; 52(6):749-766. PubMed ID: 37403798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opening up new VISTAs: V-domain immunoglobulin suppressor of T cell activation (VISTA) targeted near-infrared photoimmunotherapy (NIR-PIT) for enhancing host immunity against cancers.
    Wakiyama H; Furusawa A; Okada R; Inagaki F; Kato T; Furumoto H; Fukushima H; Okuyama S; Choyke PL; Kobayashi H
    Cancer Immunol Immunother; 2022 Dec; 71(12):2869-2879. PubMed ID: 35445836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
    Deng J; Li J; Sarde A; Lines JL; Lee YC; Qian DC; Pechenick DA; Manivanh R; Le Mercier I; Lowrey CH; Varn FS; Cheng C; Leib DA; Noelle RJ; Mabaera R
    Cancer Immunol Res; 2019 Jul; 7(7):1079-1090. PubMed ID: 31088847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.
    Hosseinkhani N; Derakhshani A; Shadbad MA; Argentiero A; Racanelli V; Kazemi T; Mokhtarzadeh A; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():676181. PubMed ID: 34093577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain.
    Clark PA; Sriramaneni RN; Bates AM; Jin WJ; Jagodinsky JC; Hernandez R; Le T; Jeffery JJ; Marsh IR; Grudzinski JJ; Aluicio-Sarduy E; Barnhart TE; Anderson BR; Chakravarty I; Arthur IS; Kim K; Engle JW; Bednarz BP; Weichert JP; Morris ZS
    Radiat Res; 2021 Jun; 195(6):522-540. PubMed ID: 33826741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer.
    Hou Z; Pan Y; Fei Q; Lin Y; Zhou Y; Liu Y; Guan H; Yu X; Lin X; Lu F; Huang H
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):517-531. PubMed ID: 33237432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Benzimidazoles as Potent Small-Molecule Inhibitors and Degraders of V-Domain Ig Suppressor of T-Cell Activation (VISTA).
    Wang T; Wang K; Zhang Y; Zhang K; Cai S; Jiang S; Xiao Y; Zhang X
    J Med Chem; 2023 Sep; 66(17):11881-11892. PubMed ID: 37594853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.